Novartis twin drug setbacks pile pressure on pipeline and CEO

Novartis is facing significant pressure on its pipeline and leadership following twin drug setbacks. These developments have increased the scrutiny on the CEO as the company navigates these pharmaceutical challenges. The simultaneous failures of two key drug candidates have created a demanding environment for the organization's strategic goals. Consequently, the company must now address these losses to stabilize its future growth prospects and maintain investor confidence amidst the current operational difficulties facing the Novartis pipeline.